Literature DB >> 29767396

Are lactoferrin receptors in Gram-negative bacteria viable vaccine targets?

Clement Chan1, Vahid F Andisi1, Dixon Ng1, Nick Ostan2, Warren K Yunker3, Anthony B Schryvers4.   

Abstract

A number of important Gram-negative pathogens that reside exclusively in the upper respiratory or genitourinary tract of their mammalian host rely on surface receptors that specifically bind host transferrin and lactoferrin as a source of iron for growth. The transferrin receptors have been targeted for vaccine development due to their critical role in acquiring iron during invasive infection and for survival on the mucosal surface. In this study, we focus on the lactoferrin receptors, determining their prevalence in pathogenic bacteria and comparing their prevalence in commensal Neisseria to other surface antigens targeted for vaccines; addressing the issue of a reservoir for vaccine escape and impact of vaccination on the microbiome. Since the selective release of the surface lipoprotein lactoferrin binding protein B by the NalP protease in Neisseria meningitidis argues against its utility as a vaccine target, we evaluated the release of outer membrane vesicles, and transferrin and lactoferrin binding in N. meningitidis and Moraxella catarrhalis. The results indicate that the presence of NalP reduces the binding of transferrin and lactoferrin by cells and native outer membrane vesicles, suggesting that NalP may impact all lipoprotein targets, thus this should not exclude lactoferrin binding protein B as a target.

Entities:  

Keywords:  Antimicrobial peptides; Lactoferrin-binding protein; Transferrin binding protein; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29767396     DOI: 10.1007/s10534-018-0105-7

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  1 in total

Review 1.  Stealthy microbes: How Neisseria gonorrhoeae hijacks bulwarked iron during infection.

Authors:  Julie Lynn Stoudenmire; Ashley Nicole Greenawalt; Cynthia Nau Cornelissen
Journal:  Front Cell Infect Microbiol       Date:  2022-09-15       Impact factor: 6.073

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.